LifeWealth Investments LLC Purchases Shares of 14,001 Pfizer Inc. (NYSE:PFE)

LifeWealth Investments LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,001 shares of the biopharmaceutical company's stock, valued at approximately $371,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $28,000. Finally, Noble Wealth Management PBC bought a new position in Pfizer in the 4th quarter worth about $31,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

Shares of PFE stock traded up $0.12 on Thursday, hitting $23.30. 13,077,289 shares of the stock traded hands, compared to its average volume of 40,988,961. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a 50 day simple moving average of $23.22 and a two-hundred day simple moving average of $25.11. The firm has a market cap of $132.49 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.38%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.